Investigator Responsibilities in Clinical Research

REFERENCES

1. 1.↵
   Trends, charts, and maps. US National Library of Medicine. clinicaltrials.gov/ct2/resources/trends. Published July 2019. Accessed July 25, 2019.
2. 2.↵
   US Food and Drug Administration. CFR – Code of Federal Regulations Title 21. www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm. Updated September 19, 2019. Accessed July 18, 2019.
3. 3.↵
   International Conference on Harmonisation Good Clinical Practice. Good Clinical Practice Network. ichgcp.net/. Accessed July 18, 2019.
4. 4.↵
   Form 1572. US Food and Drug Administration. www.fda.gov/media/71816/download. Accessed July 25, 2019.
5. 5.↵
   Warning letters. US Food and Drug Administration. www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters. Accessed July 25, 2019.
6. 6.↵
   Responsibilities of sponsors and investigators. Selecting investigators and monitors. 21 CFR §312.53. US Food and Drug Administration. www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.53. Updated September 19, 2019. Accessed July 25, 2019.
7. 7.↵
   Responsibilities of sponsors. Selecting investigators and monitors. 21 CFR §812.43. US Food and Drug Administration. www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=812.43. Updated September 19, 2019. Accessed July 25, 2019.
8. 8.↵
   1. Eckstein S

   ICH Good Clinical Practice Guideline. In: Eckstein S, ed. Manual for Research Ethics Committees. 6th ed. Cambridge, UK: Cambridge University Press; 2003.
9. 9.↵
   Investigator responsibilities – protecting the rights, safety, and welfare of study subjects. Guidance for industry. US Food and Drug Administration. www.fda.gov/regulatory-information/search-fda-guidance-documents/investigator-responsibilities-protecting-rights-safety-and-welfare-study-subjects. Published October 2009. Updated April 12, 2019. Accessed October 12, 2019.
10. 10.↵
    Kefauver-Harris amendments revolutionized drug development. US Food and Drug Administration. www.fda.gov/consumers/consumer-updates/kefauver-harris-amendments-revolutionized-drug-development. Accessed October 12, 2019.
11. 11.↵
    1. Kim JH,
    2. Scialli AR

    . Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicol Sci. 2011 Jul;122(1):1-6. doi: 10.1093/toxsci/kfr088.

    OpenUrlCrossRefPubMed
12. 12.↵
    Protection of human subjects. 21 CFR §50. US Food and Drug Administration. www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=50. Updated September 19, 2019. Accessed October 12, 2019.
13. 13.↵
    Institutional review boards. 21 CFR §56. US Food and Drug Administration. www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=56. Updated September 19, 2019. Accessed October 12, 2019.
14. 14.↵
    Investigator recordkeeping and record retention. 21 CFR §312.62. US Food and Drug Administration. www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.62. Updated September 19, 2019. Accessed October 12, 2019.
15. 15.↵
    Investigator reports. 21 CFR §312.64. US Food and Drug Administration. www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.64. Updated September 19, 2019. Accessed October 12, 2019.
16. 16.↵
    Reports. 21 CFR §812.150. US Food and Drug Administration. www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=812.150. Updated September 19, 2019. Accessed October 12, 2019.
17. 17.↵
    Financial disclosure by clinical investigators. 21 CFR §54. US Food and Drug Administration. www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=54. Updated September 19, 2019. Accessed October 12, 2019.
18. 18.↵
    Specific responsibilities of investigators. 21 CFR §812.110. US Food and Drug Administration. www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=812.110. Updated September 19, 2019. Accessed October 12, 2019.
19. 19.↵
    Inspection of investigator's records and reports. 21 CFR §312.68. US Food and Drug Administration. www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.68. Updated September 19, 2019. Accessed October 12, 2019.
20. 20.↵
    Inspections. 21 CFR §812.145. US Food and Drug Administration. www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=812.145. Updated September 19, 2019. Accessed October 12, 2019.
21. 21.
    FDA Form 483 frequently asked questions. US Food and Drug Administration. www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/fda-form-483-frequently-asked-questions. Accessed February 13, 2020.
22. 22.
    Disqualification of a clinical investigator. 21 CFR §312.70. US Food and Drug Administration. www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.70. Updated September 19, 2019. Accessed October 12, 2019.
23. 23.
    Disqualification of a clinical investigator. 21 CFR §812.119. US Food and Drug Administration. www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=812.119. Updated September 19, 2019. Accessed October 12, 2019.
24. 24.↵
    FDA debarment list (drug product applications). US Food and Drug Administration. www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/fda-debarment-list-drug-product-applications. Updated December 20, 2019. Accessed February 13, 2020.
25. 25.↵
    1. Mathews AW.

    FDA panel urges prominent warning label for antibiotic. The Wall Street Journal. May 19, 2006. www.wsj.com/articles/SB114799677462757266. Accessed February 13, 2020.
26. 26.↵
    1. Ross DB.

    The FDA and the case of Ketek. N Engl J Med. 2007 Apr 19;356(16):1601-1604. doi: 10.1056/NEJMp078032.

    OpenUrlCrossRefPubMedWeb of Science